Carcinogenesis, Teratogenesis & Mutagenesis ›› 2016, Vol. 28 ›› Issue (4): 255-261.doi: 10.3969/j.issn.1004-616x.2016.04.002

Previous Articles     Next Articles

Effects of celecoxib on proliferation and invasion of T cell lymphoma

MA Ming1, YANG Xingxiao2, WANG Xuexiao3, LIU Lihua3, ZHAO Lianmei3, DU Yanyan1, SHAN Baoen3   

  1. 1. Clinical Laboratory of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
    2. Department of Infection Management of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
    3. Research Center of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
  • Received:2015-11-17 Revised:2016-02-25 Online:2016-07-31 Published:2016-07-31

Abstract: OBJECTIVE: To investigate the effect of celecoxib on proliferation, chemotherapy sensitivity and invasion of T cell lymphoma. METHODS: Jurkat and Hut78 cells were treated with celecoxib for 24, 48 and 72 h, and their proliferation activity and chemotherapy sensitivity were detected using the MTT method. In addition, apoptotic rates of the treated cells were analyzed using flow cytometry. Transwell chamber was used to investigate the invasion of cells which were treated with celecoxib for 48 h. Expression of P38, P65, Bcl-2, Bax, MDR1, MMP2 and MMP9 in treated cells were investigated using quantitative real-time PCR (qPCR) and Western blot. RESULTS: After treatment with celecoxib, growth of Jurkat and Hut78 cells was inhibited in a dose-and time-dependent manner, and their chemotherapy sensitivity was elevated. Consequently, the apoptotic rates of the treated cells were also higher than the control. The number of treated cells that passed through Transwell chamber was significantly less than control (P<0.01). The qPCR and Western blot analyses showed that expression of P65, Bax, MDR1, Bcl-2, MMP2 and MMP9 were all down-regulated, whereas P38 and Bax were up-regulated in the treated cells compared with control(P<0.05). CONCLUSION: Celecoxib has inhibitory effect on proliferation and invasion of T cell lymphoma. Therefore, it may have a broad prospect for clinical treatment of T cell lymphoma.

Key words: celecoxib, T cell lymphoma, proliferation, invasion

CLC Number: